Cargando…
P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428760/ http://dx.doi.org/10.1097/01.HS9.0000969220.98838.e7 |
| _version_ | 1785090546852691968 |
|---|---|
| author | Desai, Pinkal Lonial, Sagar Cashen, Amanda Kamdar, Manali Blachly, James S. Flinn, Ian W. O’brien, Susan Garcia, Jacqueline Korde, Neha Moslehi, Javid Wey, Margaret Cheung, Patricia Sharma, Shringi Olabode, Damilola Chen, Hong Ali Syed, Firasath Liu, Mary Saeh, Jamal Tibes, Raoul Andrade, Marcio Kadia, Tapan |
| author_facet | Desai, Pinkal Lonial, Sagar Cashen, Amanda Kamdar, Manali Blachly, James S. Flinn, Ian W. O’brien, Susan Garcia, Jacqueline Korde, Neha Moslehi, Javid Wey, Margaret Cheung, Patricia Sharma, Shringi Olabode, Damilola Chen, Hong Ali Syed, Firasath Liu, Mary Saeh, Jamal Tibes, Raoul Andrade, Marcio Kadia, Tapan |
| author_sort | Desai, Pinkal |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428760 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104287602023-08-17 P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY Desai, Pinkal Lonial, Sagar Cashen, Amanda Kamdar, Manali Blachly, James S. Flinn, Ian W. O’brien, Susan Garcia, Jacqueline Korde, Neha Moslehi, Javid Wey, Margaret Cheung, Patricia Sharma, Shringi Olabode, Damilola Chen, Hong Ali Syed, Firasath Liu, Mary Saeh, Jamal Tibes, Raoul Andrade, Marcio Kadia, Tapan Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428760/ http://dx.doi.org/10.1097/01.HS9.0000969220.98838.e7 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Desai, Pinkal Lonial, Sagar Cashen, Amanda Kamdar, Manali Blachly, James S. Flinn, Ian W. O’brien, Susan Garcia, Jacqueline Korde, Neha Moslehi, Javid Wey, Margaret Cheung, Patricia Sharma, Shringi Olabode, Damilola Chen, Hong Ali Syed, Firasath Liu, Mary Saeh, Jamal Tibes, Raoul Andrade, Marcio Kadia, Tapan P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY |
| title | P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY |
| title_full | P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY |
| title_fullStr | P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY |
| title_full_unstemmed | P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY |
| title_short | P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY |
| title_sort | p579: safety, tolerability, pharmacokinetics, and preliminary antitumor activity of azd5991 in relapsed/ refractory hematologic malignancies: a phase 1 first-in-human study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428760/ http://dx.doi.org/10.1097/01.HS9.0000969220.98838.e7 |
| work_keys_str_mv | AT desaipinkal p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT lonialsagar p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT cashenamanda p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT kamdarmanali p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT blachlyjamess p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT flinnianw p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT obriensusan p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT garciajacqueline p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT kordeneha p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT moslehijavid p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT weymargaret p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT cheungpatricia p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT sharmashringi p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT olabodedamilola p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT chenhong p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT alisyedfirasath p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT liumary p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT saehjamal p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT tibesraoul p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT andrademarcio p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy AT kadiatapan p579safetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofazd5991inrelapsedrefractoryhematologicmalignanciesaphase1firstinhumanstudy |